date:Aug 18, 2012
EFSAs Dietetic Products, Nutrition and Allergies (NDA) panel dismissed Mercks appeal that argued its submission should have been accepted on the grounds that:
its healthy versus diseased study population data was valid
bioavailability data was valid
biomarkers and demonstration of physical effects were valid.
The NDA rejected Mercks glucosamine-joint health claim in May this year. The company did not indicate how the decision may affect marketing around products like the JointCare it sells